Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.355
-0.045 (-3.21%)
At close: Aug 1, 2025, 4:00 PM
1.350
-0.005 (-0.37%)
After-hours: Aug 1, 2025, 4:10 PM EDT

Company Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.

The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers.

It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug.

Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals logo
CountryUnited States
Founded1996
IPO DateJul 1, 2021
IndustryBiotechnology
SectorHealthcare
Employees61
CEODaniel O'Connell

Contact Details

Address:
1210-1220 Washington St., Suite 210
Newton, Massachusetts 02465
United States
Phone617 344 4190
Websiteacumenpharm.com

Stock Details

Ticker SymbolABOS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code0001576885
CUSIP Number00509G209
ISIN NumberUS00509G2093
Employer ID36-4108129
SIC Code2836

Key Executives

NamePosition
Daniel J. O'Connell M.B.A.Chief Executive Officer and Director
Dr. James Doherty Ph.D.President and Chief Development Officer
Matt ZugaChief Financial Officer and Chief Business Officer
Dr. Grant A. Krafft Ph.D.Co-Founder
Dr. Caleb E. Finch Ph.D.Co-Founder
Dr. William L. Klein Ph.D.Co-Founder
Russell Barton M.S.Chief Operating Officer
Kelly CarranzaVice President, Finance and Accounting and Corporate Controller
Alex Braun M.B.A.Vice President and Head of Investor Relations
Derek M. Meisner Esq., J.D.Chief Legal Officer and Corporate Secretary

Latest SEC Filings

DateTypeTitle
Jul 15, 20258-KCurrent Report
Jun 5, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
Apr 23, 2025ARSFiling
Apr 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 23, 2025DEF 14AOther definitive proxy statements
Mar 31, 2025SCHEDULE 13D/AFiling
Mar 27, 2025S-8Securities to be offered to employees in employee benefit plans
Mar 27, 202510-KAnnual Report